SM-102: Optimized Lipid Nanoparticle Component for mRNA Delivery

Executive Summary: SM-102 is a synthetic, ionizable lipid used in lipid nanoparticles (LNPs) for mRNA vaccine delivery, enabling efficient endosomal escape and cellular uptake (Wang et al., 2022). It exhibits high solubility in ethanol (≥175.8 mg/mL) and is insoluble in DMSO or water, requiring storage at or below -20°C (APExBIO). Mass spectrometry and NMR confirm its ≥98% purity. Machine learning models have benchmarked SM-102's delivery efficiency against alternative lipids in vivo, providing a quantitative basis for selection (DOI). SM-102 is supplied by APExBIO under SKU C1042 for research use only.

Biological Rationale

Lipid nanoparticles (LNPs) are the primary vehicles for mRNA vaccine delivery. They protect mRNA from degradation and enable intracellular delivery. A successful LNP system consists of four main components: cholesterol, DSPC, PEG-lipid, and an ionizable lipid (Wang et al., 2022). The ionizable lipid, such as SM-102, is critical for mRNA binding, endosomal escape, and controlled release. SM-102's molecular structure—heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate—enables it to become positively charged at acidic pH, facilitating complexation with negatively charged mRNA and subsequent release within the cytosol. The advent of LNPs, and specifically the development of optimized ionizable lipids like SM-102, has accelerated the deployment of clinical mRNA vaccines, including those for COVID-19 (Wang et al., 2022).

Mechanism of Action of SM-102

SM-102 acts as a cationic, ionizable lipid within LNP formulations. Upon formulation, it binds mRNA via electrostatic interactions. After administration, LNPs are endocytosed by target cells. The acidic endosomal environment protonates SM-102, increasing its positive charge and promoting endosomal membrane disruption. This enables mRNA release into the cytosol, where translation occurs (Wang et al., 2022). The unique molecular structure of SM-102 enhances its ability to aggregate into stable nanoparticles and efficiently mediate mRNA release. Structural optimization of SM-102 was informed by molecular modeling and experimental screening, as described in recent machine learning-guided studies (DOI).

Evidence & Benchmarks

• SM-102 demonstrates high mRNA encapsulation efficiency and robust endosomal escape when formulated in LNPs (Wang et al., 2022, DOI).
• When compared to other ionizable lipids (e.g., MC3), SM-102 achieves efficient mRNA delivery, though MC3 may induce higher IgG titers in certain in vivo models (Wang et al., 2022, DOI).
• Machine learning models accurately predict formulation performance, validating SM-102’s efficacy and identifying critical substructures for LNP function (Wang et al., 2022, DOI).
• SM-102 is confirmed ≥98% pure by mass spectrometry and NMR (APExBIO, product page).
• SM-102 is insoluble in DMSO/water but highly soluble in ethanol (≥175.8 mg/mL), supporting flexible formulation workflows (APExBIO).

For a broader discussion of benchmarking and scenario-driven workflows, see Optimizing mRNA Delivery: Scenario-Driven Best Practices, which extends this article with practical case studies and troubleshooting guides.

Applications, Limits & Misconceptions

SM-102 is primarily used in the development of mRNA vaccines and therapeutics, including viral and cancer vaccines. It is suitable for research-scale LNP formulation and in vivo/ex vivo mRNA delivery studies. Its robust performance and validated purity make it a standard in preclinical mRNA vaccine research. However, alternative ionizable lipids may outperform SM-102 in specific models or applications, and each formulation must be empirically validated (Wang et al., 2022).

Common Pitfalls or Misconceptions

• SM-102 is not soluble in DMSO or water: Attempting to dissolve SM-102 in these solvents leads to failed formulations (APExBIO).
• Long-term storage of SM-102 solutions is not recommended: Degradation or aggregation may occur; always prepare fresh solutions (APExBIO).
• Not all LNPs with SM-102 perform equally: Delivery efficiency depends on N/P ratio, helper lipid composition, and particle size (Wang et al., 2022).
• SM-102 is for research use only: It is not approved for clinical or therapeutic use in humans (APExBIO).
• Performance may differ in animal vs. cell models: In vivo results may not always translate directly from in vitro experiments (Wang et al., 2022).

This article clarifies these points and updates recent guides such as SM-102: Optimized Lipid Nanoparticle (LNP) Component for..., which primarily focused on mechanistic aspects, by adding new machine learning-derived benchmarks.

Workflow Integration & Parameters

For optimal mRNA encapsulation, SM-102 is dissolved in ethanol at concentrations up to ≥175.8 mg/mL. Typical LNP formulation protocols combine SM-102 with cholesterol, DSPC, and PEG-lipid at molar ratios optimized for mRNA payload and target cell line (Wang et al., 2022). The N/P ratio (nitrogen in lipid to phosphate in mRNA) is a critical parameter; a 6:1 ratio was benchmarked in vivo for comparative studies with MC3 lipids. Formulations are generally extruded or microfluidically mixed under cold conditions to promote uniform nanoparticle size (typically 60–100 nm). Storage of SM-102 should be at -20°C or lower, and shipping is under blue ice for small molecules and dry ice for modified nucleotides (APExBIO).

Workflow integration details, including advanced troubleshooting and predictive analytics, are further discussed in SM-102 Lipid Nanoparticles: Optimizing mRNA Delivery Work..., which this article updates with additional ML-driven evidence and purity validation benchmarks.

Conclusion & Outlook

SM-102 (APExBIO, C1042) is a validated, high-purity ionizable lipid essential for modern mRNA vaccine research. Its mechanism of endosomal escape and ease of workflow integration make it a staple for LNP-based mRNA delivery systems. Ongoing advances in machine learning-driven formulation and molecular modeling promise further optimization and expanded applications. For detailed specifications and procurement, consult the SM-102 product page at APExBIO.